The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Phase II trial of luspatercept in myelofibrosis-associated anemia
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the results of a trial (NCT03194542) of luspatercept to treat anemia in myelofibrosis (MF). Myelofibrosis is characterized by progressive bone marrow failure, with approximately 60% of patients developing anemia within a year of diagnosis. These patients, who typically rely on transfusions, have a worse quality of life and poor survival outcomes. To address the unmet need for MF-associated anemia therapy, luspatercept, an erythroid maturation agent, was trialed in the Phase II ACE-536-MF-001 trial. The treatment was well tolerated and there was evidence of durable activity in patients with anemia, either as a single agent or in combination with ruxolitinib. These longer-term results support the use of luspatercept for MF-associated anemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
